Director Frances Arnold filed a Form 4 with the SEC on September 3, 2026, disclosing the sale of 1,000 shares of Generate Biomedicines, Inc. common stock on September 1, 2026, under a pre-established Rule 10b5-1 trading plan.
Key Highlights
- Transaction: Frances Arnold disposed of 1,000 shares of Generate Biomedicines common stock on September 1, 2026.
- Weighted average price: Shares were sold at a weighted average price of $16.002, with individual transactions ranging from $16.00 to $16.01 per share.
- 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
- Direct ownership following sale: Arnold directly holds 231,472 shares of common stock following the reported transaction.
- Indirect ownership: Arnold indirectly holds 232,472 shares through The Frances Arnold 2010 Irrevocable Trust, with a disclaimer of beneficial ownership except to the extent of her pecuniary interest.
Frances Arnold's Share Sale and Ownership at Generate Biomedicines
According to the filing, Frances Arnold, identified as a Director of Generate Biomedicines, Inc. (NASDAQ:GENB), sold 1,000 shares of the company's common stock on September 1, 2026. The transaction was coded "S" (sale) in Table I of the Form 4. The reported price of $16.002 is a weighted average, with the shares sold across multiple transactions at prices ranging from $16.00 to $16.01 per share. The filing notes that Arnold undertakes to provide full information on the number of shares sold at each separate price upon request.
The filing discloses that the sale was effected pursuant to a Rule 10b5-1 trading plan that Arnold adopted on March 13, 2026. Following the transaction, Arnold directly holds 231,472 shares. In addition, the filing reports indirect beneficial ownership of 232,472 shares held through The Frances Arnold 2010 Irrevocable Trust. The filing states that Arnold "disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of her pecuniary interest therein, if any." The filing was signed by Michael Wolf as Attorney-in-Fact on September 3, 2026.
What Was Disclosed
The Form 4 filed on September 3, 2026, reports a sale of 1,000 shares of Generate Biomedicines common stock by Director Frances Arnold on September 1, 2026, at a weighted average price of $16.002 per share, executed under a pre-established 10b5-1 plan.




Please wait processing your request...